Outlook Therapeutics, Inc. Gains 51.83%
Mon, Feb 08, 2021 at 05:30 PM
Outlook Therapeutics, Inc. (OTLK:NASDAQ) rocketted at $3.31, a gain of 51.8%. On Fri 05 Feb 21, OTLK:NASDAQ touched a New 2-Week High of $2.18. The stock appeared on our News Catalysts scanner on Thu 04 Feb 21 at 10:32 AM in the 'MISCELLANEOUS' category. From Fri 22 Jan 21, the stock recorded 60.00% Up Days and 54.55% Green Days
About Outlook Therapeutics, Inc. (OTLK:NASDAQ)
Oncobiologics Inc is a clinical stage biopharmaceutical company. It is focused on identifying, developing, manufacturing and commercializing complex mAb therapeutics. The company has introduced BioSymphony Platform to produce high-quality innovative and biosimilar mAb candidates in an efficient and cost-effective manner.
Top 10 Gainers:
- Ocugen, Inc. (OCGN:NASDAQ), 201.14%
- Aeterna Zentaris Inc. (AEZS:NASDAQ), 200.9%
- ARYA Sciences Acquisition Corp. (ARYA:NASDAQ), 100.09%
- CRH Medical Corporation (CRHM:NYSEMKT), 79.82%
- BSQUARE Corporation (BSQR:NASDAQ), 78.37%
- Zosano Pharma Corporation (ZSAN:NASDAQ), 75.45%
- AEI (AEI:NASDAQ), 74.38%
- Sino-Global Shipping America, Ltd. (SINO:NASDAQ), 64.67%
- VJET (VJET:NASDAQ), 60.5%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 51.83%